Alnylam Pharmaceuticals Inc (ALNY) is overvalued and BeOne Medicines Ltd ADR (ONC) is overvalued.
Both trade above our estimate of their intrinsic value. ALNY is the closer of the two: -37%, against -65% for ONC.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 7.4% (average of 3 methods) values the shares at $184.17; the price of $251.65 is 37% above that value, and 83% of that value comes from beyond year five.
Leak Score 71/100 on 9 of 12 signals
Discounting its cash flows at 8.5% (average of 3 methods) values the shares at $223.46; the price of $368.08 is 65% above that value, and 79% of that value comes from beyond year five.
Leak Score 43/100 on 3 of 12 signals
| Metric | ALNY | ONC |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Price | $251.65 | $368.08 |
| Intrinsic value | $184.17 | $223.46 |
| Margin of safety | -37% | -65% |
| Leak Score | 71/100 (9/12) | 43/100 (3/12) |
| Market cap | $33.7B | $38.4B |
| Revenue growth, 5 years | 49.8% | 76.9% |
| Operating margin | 20.8% | 15.1% |
| Net margin | 16.8% | 10.7% |
| Return on equity | 100.7% | 14.7% |
| Debt to equity | 2.21 | 0.40 |
| P/E | 42.5x | 64.7x |
| Forward P/E | 25.0x | 36.7x |
| P/B | 24.9x | 8.0x |